BioLife Solutions (BioLife Solutions) Total Current Assets : $120.6 Mil (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is BioLife Solutions Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. BioLife Solutions's total current assets for the quarter that ended in Dec. 2023 was $120.6 Mil.

BioLife Solutions Total Current Assets Historical Data

The historical data trend for BioLife Solutions's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Total Current Assets Chart

BioLife Solutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

24.11

114.71

126.09

138.45

120.60

BioLife Solutions Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															138.45	132.79	120.31	116.82	120.60

BioLife Solutions Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

BioLife Solutions's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	51.695	+	18.657	+	43.456	+	6.796
	=	120.6

BioLife Solutions's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	51.695	+	18.657	+	43.456	+	6.796
	=	120.6

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

BioLife Solutions (NAS:BLFS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

BioLife Solutions's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	51.695	-	75.051	+	0.75 * 18.657	+	0.5 * 43.456
=	12.4

BioLife Solutions Total Current Assets Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLife Solutions (BioLife Solutions) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

BJX1:Germany

Address

3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021

Website

https://www.biolifesolutions.com

BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.

Executives

Geraint Phillips	officer: SVP, Global Operations	3303 MONTE VILLA, #310, BOTHELL WA 98021
Sarah Aebersold	officer: VP, Global Human Resources	BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman	officer: Chief Financial Officer	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Greef Roderick De	director
Aby J. Mathew	officer: Chief Tech. Officer & Sr. VP	3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard	officer: Vice President, Marketing	3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster	officer: Vice President of Operations	C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Michael Rice	director, officer: President & CEO	C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p.	10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Garrie Richardson	officer: Chief Revenue Officer	3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Marcus Schulz	officer: Vice President, Global Sales	3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick	director	16719 NE 139TH PLACE, WOODINVILLE WA 98072
Amy Duross	director	8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Timothy L. Moore	director	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami	director	SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023